Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have been for non-cancer drugs and indications. This represents mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Macklis, Paul C., Dulmage, Brittany, Evans, Brady, Rosenbach, Misha, Gudjonsson, Johann E., Kaffenberger, Benjamin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419407/
https://www.ncbi.nlm.nih.gov/pubmed/32557274
http://dx.doi.org/10.1007/s40268-020-00311-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419407/
https://www.ncbi.nlm.nih.gov/pubmed/32557274
http://dx.doi.org/10.1007/s40268-020-00311-6

Ejemplares similares